key: cord-0826744-acjm09tm authors: Paul, Diptanu; Gupta, Akshita; Rooge, Sheetalnath; Gupta, Ekta title: Performance evaluation of Automated Chemiluminescence Immunoassay based Antigen detection – moving towards more reliable ways to predict SARS-CoV-2 infection date: 2021-09-22 journal: J Virol Methods DOI: 10.1016/j.jviromet.2021.114299 sha: 28a3af503afdb84694ddbade1405d5f9db584971 doc_id: 826744 cord_uid: acjm09tm Real-time reverse transcription- polymerase chain reaction (RT-PCR) has been the most reliable armoury for the diagnosis of COVID-19, considered to be the reference standard but fails to reproduce the correct predictability about the infectivity of the disease every time. Antigen detection however puts foothold in this aspect even though lacks in sensitivity, especially conventional Rapid Antigen Tests (RATs). Recently developed Chemiluminescence Immunoassay (CLIA) based antigen detection tests are promising and displayed better sensitivity. In the current study we have evaluated VITROS® SARS-CoV-2 Ag Test CLIA Kit, which was tested on 148 patient’s samples attended to a tertiary care centre for testing of SARS-CoV-2. The performance of the kit was evaluated in comparison to RT-PCR and RAT and found to be a good test for antigen detection, best within the first few days of infection. The test has shown sensitivity of 94.3% and specificity of 100% in samples with corresponding Ct values of ≤25 by RT-PCR, which corresponds to high viral load and can predict ability of spreading the disease by the patients. With the results being semiquantitative along with improved sensitivity it can replace RATs for antigen detection for screening, provided good laboratory set up is included under consideration. Real-time reverse transcription-polymerase chain reaction (RT-PCR) has a pivotal role in detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is considered to be the reference standard test for diagnosis of SARS-CoV-2 but to maintain its analysis throughput sufficient manpower, skilled operators, costly machines with consumables and strict biosafety measures are required. Moreover, in spite of having high sensitivity and specificity RT-PCR do not always reflect the true infectivity of the patients, as the RT-PCR test can detect too low levels of nucleic acid (RNA of SARS-CoV-2) of the virus, suggesting low viral load, and hence are very unlikely to cause infection in others. On the other hand, antigen based tests are used more often as a screening test despite their variable sensitivity and specificity. Rapid Antigen Tests (RATs) are faster, easy to interpret, less expensive, minimal training is required to adopt its use and it can pick up active ongoing infections too. Currently there are approximately 175 RAT kits available,(1) but the average sensitivity of RATs is only 56.20% (95% CI 29.50 to 79.80%), according to a recently published Cochrane study. (2) If the antigen detection is done on a better platform like Chemiluminescence Immunoassay (CLIA), the sensitivity increases up to 96.40%(3), which helps in better detection of SARS-CoV-2 antigens during the phase of early infection. Moreover, to perform RAT and RT-PCR together, two separate samples are required. First dry nasopharyngeal (NP) swab is required for RAT and then separate nasopharyngeal (NP) and oropharyngeal (OP) swabs are required to take for RT-PCR. This double sample collection can be difficult and inconvenient for patients, which J o u r n a l P r e -p r o o f is not required for antigen detection by CLIA as single NP and OP swab sampling is sufficient for performing both CLIA and RT-PCR. Therefore, in this current study we have evaluated the performance of one newly developed automated CLIA based antigen detection test -"VITROS ® SARS-CoV-2 Ag Test CLIA Kit" (VITROS). We also evaluated the performance of SARS-CoV-2 antigen detection methods; CLIA based VITROS and lateral flow assay based RAT in comparison to the reference standard RT-PCR test and also compared the performance of VITROS with RAT. All consecutive patients with clinical sign and symptoms suggestive for COVID-19 infection who visited the Outpatient Department of the Institute, as per the National guidelines(4) for testing were included after obtaining informed consent for the study. The study was approved by the Institutional Review Board of the Institute of Liver and Biliary Sciences and conducted in accordance with the Declaration of Helsinki. Two NP swabs and one OP swab were collected from each patient simultaneously. One NP swab was used for RAT. The remaining NP swab and OP swab were transferred into a tube of viral transport medium (VTM). This VTM tube was then sent to our lab for VITROS and RT-PCR. All samples were collected as per the available guidelines,(5) with due biosafety precautions. The specimens were properly packaged and maintained in cold chain during transportation. Clinical and demographic data of all the patients were also collected and evaluated. A total of 148 samples were tested for SARS-CoV-2 Antigen by RAT and VITROS and confirmation of COVID-19 was done by viral RNA detection by RT-PCR. RAT was performed at the point of collection and in the lab two aliquots were prepared from collected VTM tube fluids. One aliquot was used for VITROS and another aliquot was used for RT-PCR on the same day of collection. Aliquots were stored at -80°C for future use after performing all the tests. RAT was performed using Angcard ® COVID-19 rapid Antigen Test kit (Angstrom ® Biotech Pvt. Ltd., Alwar, Rajasthan, India), following manufacturer's instructions. RT-PCR was performed using RealStar ® SARS-CoV-2 RT-PCR kit 1.0 (Altona ® Diagnostics, Germany) following all manufacturer's instructions and a Ct value of ≤35 for E and S gene were considered to be Positive. All the data was first entered in Microsoft Excel spreadsheet and then analysed with the help infection as confirmed by RT-PCR positivity was seen in 98 (66.20%) patients,. Baseline characteristics of the study population are described in Table 1 . The median duration of illness until RAT gave positive results was 2 days (IQR: 0-6 days) and for VITROS also it was 2 days (IQR: 0-7 days). Maximum number of positive RAT (n=19, 37.30%) samples and positive VITROS (n=28, 38.90%) samples were from patients on their 3 rd day of illness. However, 12 (16.70%) VITROS positive and eight (15.70%) RAT positive samples were collected from asymptomatic patients. Semiquantitative data of VITROS as s/co was compared with days of sample collection after onset of illness, which is depicted in Figure 4 . On comparing VITROS with RT-PCR an overall agreement was found to be 83.34% (Cohen's k: 0.67) whereas, with same criteria RAT shows an overall agreement of 44% (Cohen's k:0.53). Other statistical parameters comparing both antigen detection test methods are summarised in Table 2 . can be performed with the instrument. As a limitation of this study we can consider small study population, lack of data on disease prevalence in India and the use of single RAT kit to compare the results of antigen detection. In future, multiple platforms for antigen detection with different kits on a larger population can be done for further confirmation of our data in favour of the newly developed automated antigen detection kit and evaluation of its performance. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. SARS-CoV-2 diagnostic pipeline Rapid, pointof-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Head-to-head comparison of rapid and automated antigen detection tests for the diagnosis of SARS-CoV-2 infection ICMR. Advisory on Strategy for COVID-19 Testing in India COVID specimen collection, packaging and transportation guidelines. ncdc.gov Comparative evaluation of four SARS-CoV-2 antigen tests in hospitalized patients Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study Comparison of Rapid Antigen Tests for COVID-19. Viruses Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples Laboratory testing for the diagnosis of COVID-19 Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients None J o u r n a l P r e -p r o o f Manuscript has not been previously presented. This manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier have been met, and that each author believes that the manuscript represents honest work. Authors have no conflict of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.